Vertex Pharmaceuticals
NEWS
Vertex has declined to comment, but BioCentury received a copy of the letter the company sent to laboratories explaining.
The FDA approved Vertex’s Symdeko for cystic fibrosis in patients ages 12 and older with two copies of the F508del mutation.
Here is a look at a few important regulatory events scheduled for the month of February.
Vertex is keeping its promise of advancing triple combination treatments for patients with cystic fibrosis and investors are happy.
The effort was announced last week by the Henri A. Termeer Tribute Committee.
These stocks have been given a Strong Buy or Buy rating by 80% or more brokers.
The analyst identified Vertex and Alexion as his top two picks among large cap biotechs in 2018.
It was a pretty good year for the stock market, but how about for biotech stocks?
This year wasn’t big for mergers and acquisitions in biopharma, particularly compared to 2015 and 2016.
JOBS
IN THE PRESS